FIGO-staging is a classification system used to describe size and extent of gynaecological cancers, using the FIGO nomenclature (International Federation of Gynecology and Obstetrics).
- 0: Carcinoma in situ (CIS)
- I: Growth limited to organ of origin
- II: Invasion of surrounding organs and tissues
- III: Spread to nodes or tissues within pelvis
- IV: Distant metastasis
| Carcinoma cervix | Endometrial cancer | Carcinoma ovary | |
| Basis of staging | Clinical (examination + radiographs) | Surgical (pathologic assessment) | Surgical (pathologic assessment) |
| FIGO stages | 2018 | 2023 | 2014 |
| I | Confined to cervix – A: Microscopic – B: Macroscopic | Confined to uterine corpus – A: <1/2 Myometrium – B: >1/2 Myometrium | Limited to ovaries – A: 1 ovary – B: 2 ovaries – C: Surgical spill/Surface growth/Malignant ascites |
| II | Beyond uterus: A – upper 2/3 vagina B – parametrium | Cervical stroma | Pelvic extension |
| III | Lower 1/3 vagina &/or Pelvic wall &/or Renal involvement &/or Pelvic/para-aortic lymph nodes | Uterine serosa, Adnexa, Vagina or Lymph nodes | Abdominal extension including retroperitoneal lymph nodes and superficial liver/spleen |
| IV | A – Spread to adjacent organs B – Spread to distant organs (inguinal lymph nodes not involved) | A – Spread to adjacent organs B – Spread to distant organs including inguinal lymph nodes | Distant metastasis A – Malignant pleural effusion B – Deep liver/spleen deposits or inguinal lymph nodes |
| Treatment | |||
| I-IIA: Radical hysterectomy | I: TAH + BSO | I: TAH + BSO | |
| IIB-IV: Chemo-radiotherapy | II-IV: Extended or modified radical hysterectomy + BSO + LN dissection | II-IV: Partial removal of tumor followed by platinum chemotherapy | |
| High grade or Surgery contraindicated: Chemo-radiotherapy | Recurrent cases: Other chemotherapy and Radiotherapy |
